Medical/Pharmaceuticals
Tigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services Business
HANGZHOU, China, Nov. 10, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (Stock Codes: 300347.SZ / 3347.HK, hereinafter referred to as "Tigermed"), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, today anno...
2026-11-10 16:55
Neu Era Outlines 2027 Southeast Asia Growth Strategy Centred on Regenerative Aesthetics and Physician Education
Singapore-based aesthetics company plans to expand physician education, scientific exchange and regional partnerships from Singapore and Malaysia SINGAPORE, Nov. 10, 2026 /PRNewswire/ -- NEUVA ERA PTE LTD ("Neu Era") has outlined its 2027 growth strategy, with plans to deepen its presence in Sin...
2026-11-10 14:53
720
Panboron BNCT Opens Cross-Border BNCT Care Pathway in China
Nearly 60 treatments completed since March 2026 at China's first medical institution delivering clinical BNCT with an overseas-approved drug-and-device combination. BOAO, China, Nov. 10, 2026 /PRNewswire/ -- Panboron BNCT, an oncology healthcare enterprise under China Biotech Services Holdings L...
2026-11-10 10:19
1171
World First! LivingPHOENIX Secures China's First Medical Device Registration Certificate for Biomimetic Collagen, Ushering in the Era of Third-Generation "Biomimetic Collagen ECM"
CHENGDU, China, Nov. 10, 2026 /PRNewswire/ -- On November 6, at the 2026 Golden Panda Global Innovation and Entrepreneurship Competition, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. ("LivingPHOENIX") achieved a historic milestone: its independently developed "Sterile Bio...
2026-11-10 09:49
2104
Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder
SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for SR122, a dual GalNAc conjugated...
2026-11-10 09:00
2155
PharmaBlock CMC Lifecycle Strategy Forum: Smarter Decisions Across the Drug Development Lifecycle
Lifecycle-based CMC strategies can help biotech companies balance speed, risk and long-term asset value as programs advance globally NANJING, China, Nov. 9, 2026 /PRNewswire/ -- PharmaBlock hosted its CMC Lifecycle Strategy Forum in Nanjing on November 5 and 6, bringing together experienced phar...
2026-11-09 16:29
1671
Timing Affects Speed, Not Total Exposure
CureGene Presents Evategrel China–US PK/PD and Food-Effect Data at AHA 2026 SHANGHAI, Nov. 8, 2026 /PRNewswire/ -- Clopidogrel does not work the same way in every patient. In East Asian populations the gap is wider still: a share of patients get too little platelet inhibition at the standard dose...
2026-11-09 08:51
1313
Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Nov. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
2026-11-09 08:30
2368
Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy
* SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4W * SINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) af...
2026-11-09 08:00
2632
China's Chongqing Senior Industry Expo Showcases AI and New Services for Older Adults
CHONGQING, China, Nov. 8, 2026 /PRNewswire/ -- A news report from iChongqing.
2026-11-08 03:12
3936
VS Pharmtech Boosts Cancer Treatment Efficacy Without Adding Toxicity
SEOUL, South Korea, Nov. 6, 2026 /PRNewswire/ -- Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anticancer drugs often carry severe toxicity. Rather than developing a new anticancer drug, Park ...
2026-11-07 01:00
4407
OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
— 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refractory NSCLC — — Preliminary efficacy and safety results support further development of cesalatamig monotherapy — ROCKVILLE, Md., Nov. 6, 2026 /P...
2026-11-06 22:30
8838
Neuroendocrine Cancer Day: The Cancer Hiding in Plain Sight
SYDNEY, Australia, Nov. 6, 2026 /PRNewswire/ -- Ahead of Neuroendocrine Cancer
Day on 10 November,NeuroEndocrine Cancer Australia
2026-11-06 14:00
2366
Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 6, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced that the New Drug Application (NDA) for its core product, zemp...
2026-11-06 12:30
3389
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 6, 2026 /PRNewswire/ -- On 5 November 2026, Hong Kong Economic Journal (HKEJ), one of Hong Kong's most influential Chinese financial publications, hosted the "ESG & Sustainability Awards of Excellence 2026" ceremony. At the event, Fosun International received the "ESG & Corporate ...
2026-11-06 09:00
5366
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
SHANGHAI and HONG KONG, Nov. 6, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
2026-11-06 08:30
3420
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure
* Data across five Phase 2 studies of BRII-179, including ENSURE, ENRICH and ENHANCE, support its potential role in priming HBV-specific immune responses and improving functional cure rates with siRNA-based therapies * ENRICH prospectively reproduced the BRII-179 priming effect previously obs...
2026-11-06 08:00
5013
ABEC Launches ATB™-2100 Platform to Transform Advanced Therapy Manufacturing
BETHLEHEM, Pa., Nov. 5, 2026 /PRNewswire/ -- ABEC, a global leader in engineered solutions and services for biopharmaceutical manufacturing, today announced the commercial launch of the ATB™-2100 Advanced Therapy Bioreactor, a breakthrough single-use cell expansion technology designed to address ...
2026-11-05 23:11
2355
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Recognition Highlights Kazia's Focus on Overcoming Treatment Resistance in
Cancer
SYDNEY, Nov. 5, 2026 /PRNewswire/ -- Kazia Therapeutics Limited
2026-11-05 20:00
2514
NORROY BIOSCIENCE Showcased 11 Research Presentations at EANM' 26, Advancing Radiopharmaceutical Innovation and Global Ecosystem Collaboration
WUXI, China, Nov. 5, 2026 /PRNewswire/ -- NORROY BIOSCIENCE (NORROY), a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals, today announced that its proprietary pipelines were featured in eight Top Rated Oral Presentations (TROP) and three e-posters at ...
2026-11-05 18:00
2678
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
64133
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
29281
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
23487
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
20228